Singletto
Singletto develops and licenses Oxafence Active Protection, a materials-applied antimicrobial technology designed to integrate into existing products and manufacturing processes. Its platform enables ongoing antimicrobial performance within materials for healthcare, military, industry, and consumer applications, addressing environments where microbial exposure accumulates. The organization aims to unlock new capabilities in antimicrobial materials by partnering with manufacturers and researchers.
Facts
- HQ
- Seattle, US
- Sectors
- Biotechnology
- Founded
- 2020
- Type
- Corporation Seattle business license
- Employees
- 10
- Registered name
- Singletto Inc Seattle business license
- Stage
- Series A
- Members see funding amounts. .
- Founders
- James (Jim) Chen, MD, Thomas (Tom) Lendvay, MD
Is this your organization? Claim it
Members see Singletto's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
John Bjornson Executive Officer, Director, Co-Founder and Chief Executive Officer
-
Thomas Lendvay Executive Officer, Director, Co-Founder and Chief Medical Officer
-
James Chen Executive, Chief Scientific Officer